Genzyme/Isis On Track To Submit Severe High Cholesterol Drug Mipomersen In 1H 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
The second-generation antisense drug is four for four in positive Phase III outcomes, but in addition to lowered cholesterol, patients in those studies had elevated liver enzymes, leaving observers to wonder whether FDA will consider the side effect a manageable trade-off for filling an unmet need.
You may also be interested in...
Sanofi-Aventis Offer To Buy Genzyme Seen As Starting Point For Long Negotiation
French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.
Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.
Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.